1. Hu G, Guo M, Xu J, Wu F, Fan J, Huang Q, et al. Nanoparticles targeting macrophages as potential clinical therapeutic agents against cancer and inflammation. Frontiers in immunology. 2019;10:1998.

2. Farhood B, Geraily G, Alizadeh A. Incidence and mortality of various cancers in Iran and compare to other countries: a review article. Iranian journal of public health. 2018;47(3):309.

3. El-Kass A, Ragheb MM, Hamed SM, Turkman AM, Zaki AT. Needs and Self-Care Efficacy for Cancer Patients Suffering from Side Effects of Chemotherapy. Journal of Oncology. 2021;2021.

4. Douedi S, Carson MP. Anthracycline Medications (Doxorubicin). Stat Pearls: Stat Pearls Publishing, Treasure Island (FL). 2020.

5. Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomedicine & Pharmacotherapy. 2021;139:111708.

6. Cai F, Luis MAF, Lin X, Wang M, Cai L, Cen C, et al. Anthracycline‑induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment. Molecular and clinical oncology. 2019;11(1):15-23.

7. Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death & Disease. 2021;12(4):1-15.

8. Jian CY, Ouyang HB, Xiang XH, Chen JL, Li YX, Zhou X, et al. Naringin protects myocardial cells from doxorubicin‑induced apoptosis partially by inhibiting the p38MAPK pathway. Molecular medicine reports. 2017;16(6):9457-63.

9. Ricci MS, Zong W-X. Chemotherapeutic approaches for targeting cell death pathways. The oncologist. 2006;11(4):342.

10. López AR, Monzón P, Acerenza L. A model for the regulation of apoptosis intrinsic pathway: The potential role of the transcriptional regulator E2F in the point of no return. Journal of Theoretical Biology. 2021;525:110765.

11. Garrido‐Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. British journal of pharmacology. 2013;169(2):337-52.

12. Yuan H, Zhang X, Zheng W, Zhou H, Zhang B-Y, Zhao D. Minocycline attenuates kidney injury in a rat model of streptozotocin-induced diabetic nephropathy. Biological and Pharmaceutical Bulletin. 2016;39(8):1231-7.

13. Afshari AR, Mollazadeh H, Sahebkar A. Minocycline in Treating Glioblastoma Multiforme: Far beyond a Conventional Antibiotic. Journal of oncology. 2020;2020.

14. Gunn GB, Mendoza TR, Garden AS, Wang XS, Shi Q, Morrison WH, et al. Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Supportive Care in Cancer. 2020;28(1):261-9.

15. Pachman DR, Dockter T, Zekan PJ, Fruth B, Ruddy KJ, Ta LE, et al. A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. Supportive Care in Cancer. 2017;25(11):3407-16.

16. Piegari E, Cozzolino A, Ciuffreda LP, Cappetta D, De Angelis A, Urbanek K, et al. Cardioprotective effects of miR-34a silencing in a rat model of doxorubicin toxicity. Scientific reports. 2020;10(1):1-12.

17. Zhang G, Zha J, Liu J, Di J. Minocycline impedes mitochondrial-dependent cell death and stabilizes expression of hypoxia inducible factor-1α in spinal cord injury. Archives of medical science: AMS. 2019;15(2):475.

18. Georgiadis N, Tsarouhas K, Rezaee R, Nepka H, Kass GE, Dorne JL, et al. What is considered cardiotoxicity of anthracyclines in animal studies Corrigendum in/10.3892/or. 2020.7717. oncology reports. 2020;44(3):798-818.

19. Procópio IM, Pereira-Sampaio MA, Costa WS, Sampaio FJ, Souza DB. Histomorphometric comparison of the corpus cavernosum of rats submitted to euthanasia with ketamine and xylazine or isoflurane. Acta Cirúrgica Brasileira. 2021 Dec 8;36.

20. Argun M, Üzüm K, Sönmez MF, Özyurt A, Karabulut D, Soyersarıca Z, et al. Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats. Anatolian Journal of Cardiology. 2016;16(4):234.

21. Ramezani N, Vanaky B, Shakeri N, Soltanian Z, Fakhari Rad F, Shams Z. Evaluation of Bcl-2 and Bax Expression in the Heart of Diabetic Rats after Four Weeks of High Intensity Interval Training. Medical Laboratory Journal. 2019;13(1):15-20.

22. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3-new capabilities and interfaces. Nucleic acids research. 2012;40(15):e115-e.

23. Li N, Xie X, Hu Y, He H, Fu X, Fang T, et al. Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy. American journal of translational research. 2019;11(3):1255.

24. Abdullah CS, Alam S, Aishwarya R, Miriyala S, Bhuiyan MAN, Panchatcharam M, et al. Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration. Scientific reports. 2019;9(1):1-20.

25. Zilinyi R, Czompa A, Czegledi A, Gajtko A, Pituk D, Lekli I, et al. The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity: the role of autophagy. Molecules. 2018;23(5):1184.

26. Mitry MA, Edwards JG. Doxorubicin induced heart failure: Phenotype and molecular mechanisms. IJC heart & vasculature. 2016;10:17-24.

27. Benzer F, Kandemir FM, Ozkaraca M, Kucukler S, Caglayan C. Curcumin ameliorates doxorubicin‐induced cardiotoxicity by abrogation of inflammation, apoptosis, oxidative DNA damage, and protein oxidation in rats. Journal of biochemical and molecular toxicology. 2018;32(2):e22030.

28. He Y, Yang Z, Li J, Li E. Dexmedetomidine reduces the inflammation and apoptosis of doxorubicin-induced myocardial cells. Experimental and molecular pathology. 2020;113:104371.

29. Macedo AV, Hajjar LA, Lyon AR, Nascimento BR, Putzu A, Rossi L, et al. Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. Cardio Oncology. 2019;1(1):68-79.

30. Ceruso MS, Napolitano A, Silletta M, Mazzocca A, Valeri S, Improta L, et al. Use of cardioprotective dexrazoxane is associated with increased myelotoxicity in anthracycline-treated soft-tissue sarcoma patients. Chemotherapy. 2019;64(2):105-9.

31. Maruyama S, Shibata R, Ohashi K, Ohashi T, Daida H, Walsh K, et al. Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism. Journal of Biological Chemistry. 2011;286(37):32790-800.

32. Wang XS, Shi Q, Mendoza T, Lin S, Chang JY, Bokhari RH, et al. Minocycline reduces chemoradiation-related symptom burden in patients with non-small cell lung cancer: A phase 2 randomized trial. International Journal of Radiation Oncology* Biology* Physics. 2020;106(1):100-7.

33. Naderi Y, Panahi Y, Barreto GE, Sahebkar A. Neuroprotective effects of minocycline on focal cerebral ischemia injury: a systematic review. Neural regeneration research. 2020;15(5):773.